Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OGI NASDAQ:PBYI NASDAQ:RPHM NASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOGIOrganigram Global$2.06+4.3%$1.60$0.85▼$2.08$274.99M1.49745,874 shs1.96 million shsPBYIPuma Biotechnology$5.23+3.6%$4.44$2.32▼$6.07$263.69M1.37485,669 shs392,382 shsRPHMReneo Pharmaceuticals$1.82$1.64$0.98▼$9.21$60.84M0.21250,384 shs437,523 shsSGMTSagimet Biosciences$6.70-3.2%$7.85$1.73▼$11.41$217.82M3.351.01 million shs314,014 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOGIOrganigram Global+16.57%+10.06%+13.87%+49.24%+11.93%PBYIPuma Biotechnology+4.34%+13.23%+0.20%+40.67%+95.74%RPHMReneo Pharmaceuticals0.00%0.00%0.00%0.00%+9.64%SGMTSagimet Biosciences-5.72%+1.62%-7.86%-13.82%+145.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOGIOrganigram Global$2.06+4.3%$1.60$0.85▼$2.08$274.99M1.49745,874 shs1.96 million shsPBYIPuma Biotechnology$5.23+3.6%$4.44$2.32▼$6.07$263.69M1.37485,669 shs392,382 shsRPHMReneo Pharmaceuticals$1.82$1.64$0.98▼$9.21$60.84M0.21250,384 shs437,523 shsSGMTSagimet Biosciences$6.70-3.2%$7.85$1.73▼$11.41$217.82M3.351.01 million shs314,014 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOGIOrganigram Global+16.57%+10.06%+13.87%+49.24%+11.93%PBYIPuma Biotechnology+4.34%+13.23%+0.20%+40.67%+95.74%RPHMReneo Pharmaceuticals0.00%0.00%0.00%0.00%+9.64%SGMTSagimet Biosciences-5.72%+1.62%-7.86%-13.82%+145.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOGIOrganigram Global 0.00N/AN/AN/APBYIPuma Biotechnology 3.00Buy$7.0033.84% UpsideRPHMReneo Pharmaceuticals 0.00N/AN/AN/ASGMTSagimet Biosciences 3.00Buy$25.67283.08% UpsideCurrent Analyst Ratings BreakdownLatest RPHM, OGI, PBYI, and SGMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025SGMTSagimet BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$28.008/7/2025SGMTSagimet BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$29.007/24/2025SGMTSagimet BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.00(Data available from 9/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOGIOrganigram Global$117.47M2.35N/AN/A$2.07 per share0.99PBYIPuma Biotechnology$230.50M1.14$0.92 per share5.68$1.88 per share2.78RPHMReneo PharmaceuticalsN/AN/AN/AN/A$2.66 per shareN/ASGMTSagimet Biosciences$2M108.94N/AN/A$5.08 per share1.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOGIOrganigram Global-$33.39M$0.0540.95N/AN/A2.86%-8.19%-5.79%12/17/2025 (Estimated)PBYIPuma Biotechnology$30.28M$0.985.3413.76N/A20.38%53.15%23.51%11/6/2025 (Estimated)RPHMReneo Pharmaceuticals-$77.39M-$2.17N/AN/AN/AN/A-62.52%-56.36%N/ASGMTSagimet Biosciences-$45.57M-$1.83N/AN/AN/AN/A-39.88%-38.40%11/13/2025 (Estimated)Latest RPHM, OGI, PBYI, and SGMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q3 2025OGIOrganigram Global-$0.01-$0.03-$0.02-$0.03$68.04 million$50.49 million8/13/2025Q2 2025SGMTSagimet Biosciences-$0.52-$0.32+$0.20-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOGIOrganigram GlobalN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ARPHMReneo PharmaceuticalsN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOGIOrganigram GlobalN/A2.591.42PBYIPuma Biotechnology0.101.731.62RPHMReneo PharmaceuticalsN/A57.8657.86SGMTSagimet BiosciencesN/A17.5517.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOGIOrganigram Global34.63%PBYIPuma Biotechnology61.29%RPHMReneo Pharmaceuticals90.98%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipOGIOrganigram Global0.09%PBYIPuma Biotechnology23.30%RPHMReneo Pharmaceuticals17.90%SGMTSagimet Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOGIOrganigram Global860134.34 million134.22 millionOptionablePBYIPuma Biotechnology20050.37 million38.64 millionOptionableRPHMReneo Pharmaceuticals3033.43 million27.44 millionOptionableSGMTSagimet Biosciences832.52 million27.74 millionOptionableRPHM, OGI, PBYI, and SGMT HeadlinesRecent News About These CompaniesSagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech WeekSeptember 24, 2025 | markets.businessinsider.comSagimet Biosciences (NASDAQ:SGMT) Upgraded at Wall Street ZenSeptember 21, 2025 | marketbeat.comSagimet Biosciences Inc. (NASDAQ:SGMT) Receives $25.67 Average PT from AnalystsSeptember 19, 2025 | americanbankingnews.comSagimet Biosciences reports data from Phase 3 trial on denifanstatSeptember 17, 2025 | msn.comPositive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner AscletisSeptember 17, 2025 | globenewswire.comHere's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 WeeksSeptember 16, 2025 | zacks.comSagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 16, 2025 | marketbeat.comWall Street Zen Downgrades Sagimet Biosciences (NASDAQ:SGMT) to SellSeptember 15, 2025 | marketbeat.comSagimet Biosciences announces presentations at MASH Drug Development SummitSeptember 10, 2025 | msn.comSagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development SummitSeptember 10, 2025 | globenewswire.comAlyeska Investment Group L.P. Sells 98,069 Shares of Sagimet Biosciences Inc. $SGMTSeptember 8, 2025 | marketbeat.comWall Street Zen Upgrades Sagimet Biosciences (NASDAQ:SGMT) to "Hold"September 8, 2025 | marketbeat.comSagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 7, 2025 | seekingalpha.comSagimet Biosciences: Strong Denifanstat Pipeline Progress, Funding Overhang Keeps Stock At HoldAugust 31, 2025 | seekingalpha.comSagimet Gains Momentum As FDA Eases Path For MASH Drug DevelopmentAugust 29, 2025 | seekingalpha.comSagimet Biosciences to Participate in Two Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comSagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?August 20, 2025 | zacks.comAfter Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)August 20, 2025 | zacks.comSagimet Biosciences Enters New Sales Agreement with LeerinkAugust 15, 2025 | msn.comSagimet Biosciences Inc.: Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 13, 2025 | finanznachrichten.deSagimet Biosciences Tops Q2 EPS ForecastAugust 13, 2025 | aol.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Hot Tech Stocks With Bullish Charts and Ample UpsideBy Thomas Hughes | September 15, 2025Resideo Technologies: Institutional Activity Signals 30% UpsideBy Thomas Hughes | September 16, 2025Insiders Sell These High-Quality Stocks: Why Investors Shouldn’tBy Thomas Hughes | September 8, 2025Potential Rate Cuts Could Benefit These FirmsBy Nathan Reiff | September 8, 20253 Dividend Stocks to Hold Through Market Volatility This FallBy Chris Markoch | September 16, 2025RPHM, OGI, PBYI, and SGMT Company DescriptionsOrganigram Global NASDAQ:OGI$2.06 +0.09 (+4.31%) As of 02:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Puma Biotechnology NASDAQ:PBYI$5.23 +0.18 (+3.56%) As of 02:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Reneo Pharmaceuticals NASDAQ:RPHMReneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.Sagimet Biosciences NASDAQ:SGMT$6.70 -0.22 (-3.18%) As of 02:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AppLovin Stock Momentum Builds With $800+ Analyst Price Target Apple Stock Positioned for Holiday Gains With iPhone 17 Boost 3 Top-Rated Dividend Growth Stocks to Buy in October Top Insider Buys and Sells From September: Buy, Sell, or Hold? This ETF Weeds Out Small-Cap Underperformers Chewy Stock: Why Analysts Say Boring May Be the Best Buy Dividend ETF SCHD Draws Buyers as Fed Cuts Spark Rotation Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
